Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. The company provides its products through stockists, doctors, pharmacies, chemists, large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. It exports its products to approximately 13 countries worldwide. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
Metrics to compare | JENA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJENAPeersSector | |
---|---|---|---|---|
P/E Ratio | 18.9x | 37.7x | −0.6x | |
PEG Ratio | 0.89 | 0.47 | 0.00 | |
Price/Book | 3.6x | 5.6x | 2.6x | |
Price / LTM Sales | 3.9x | 5.7x | 3.2x | |
Upside (Analyst Target) | - | 12.9% | 45.4% | |
Fair Value Upside | Unlock | −15.7% | 7.7% | Unlock |